FFA1 (GPR40) as a therapeutic target for neural angiogenesis diseases or disorders
US11583528B2 · kind B2 · utility
0Cited by
12References
15Claims
0Family size
Inventors
Key dates
| Filing date | Feb 17, 2017 |
| Grant date | Feb 21, 2023 |
| Priority date | — |
| Expiry date | Sep 23, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/50
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The instant invention provides methods and compositions related to discovery of Free Fatty Acid Receptor 1 (FFA1) as a therapeutic target for treatment or prevention of diseases or disorders of neurons that are characterized by angiogenesis, or of vascular diseases of the eye, retinal degeneration and/or tumors more generally. Therapeutic and/or prophylactic uses and compositions of known FFA1 inhibitors, including small molecules and nucleic acid agents, are described. Methods for identification of novel FFA1 inhibitors are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.